Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET1402L1-CART in AFP+ HCC
NCT03349255Phase 1Terminated
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of et1402l1-artemis t cells in hepatocellular carcinoma (HCC) (2 arms). Primary endpoints: Number of patients with dose-limiting toxicity at 2 years and Toxicity profile of ET1402L1-CART-cell treatment at 2 years. Started Oct 2017; status: terminated.
02
Drugs
et1402l1-artemis t cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03349255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349255.